Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EBV mRNA Vaccine in Advanced EBV-Associated Tumors
NCT07101536Phase 2Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Aug 2025
- Primary completion
- Dec 2026
01
Overview
Phase 2, open-label trial in nasopharyngeal carcinoma (NPC), Natural killer T-cell lymphoma (NKTL) and gastric cancer (GC) (5 arms), sponsored by West China Hospital of Sichuan University. Primary endpoints: Dose Limiting Toxicity at 1 year and Treatment-Related Adverse Events at 1 year. Planned start Aug 2025; status: not yet recruiting.
02
Conditions
nasopharyngeal carcinoma (NPC)Natural killer T-cell lymphoma (NKTL)gastric cancer (GC)
Beyond the preview
Go deeper on NCT07101536.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07101536.